These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 28419822

  • 1. Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats.
    Jiang D, Kawagoe Y, Kuwasako K, Kitamura K, Kato J.
    Eur J Pharmacol; 2017 Jul 05; 806():91-95. PubMed ID: 28419822
    [Abstract] [Full Text] [Related]

  • 2. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
    Nakamoto M, Ohya Y, Sakima A, Yamazato M, Takishita S.
    Hypertens Res; 2007 Apr 05; 30(4):359-66. PubMed ID: 17541215
    [Abstract] [Full Text] [Related]

  • 3. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
    Kurobe H, Matsuoka Y, Hirata Y, Sugasawa N, Maxfield MW, Sata M, Kitagawa T.
    J Thorac Cardiovasc Surg; 2013 Dec 05; 146(6):1501-8. PubMed ID: 23535154
    [Abstract] [Full Text] [Related]

  • 4. Effects of vasodilators on beat-to-beat and every fifteen minutes blood pressure variability induced by noradrenaline infusion in rats.
    Jiang D, Matsuzaki M, Ida T, Kitamura K, Kato J.
    Hypertens Res; 2024 Apr 05; 47(4):1017-1023. PubMed ID: 38337004
    [Abstract] [Full Text] [Related]

  • 5. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K.
    J Cardiovasc Pharmacol; 2008 Dec 05; 52(6):555-60. PubMed ID: 19057394
    [Abstract] [Full Text] [Related]

  • 6. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun 05; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 7. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y, Hirooka Y, Sagara Y, Sunagawa K.
    Clin Exp Hypertens; 2007 Jan 05; 29(1):13-21. PubMed ID: 17190727
    [Abstract] [Full Text] [Related]

  • 8. Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.
    Kondo N, Kiyomoto H, Yamamoto T, Miyatake A, Sun GP, Rahman M, Hitomi H, Moriwaki K, Hara T, Kimura S, Abe Y, Kohno M, Nishiyama A.
    J Pharmacol Exp Ther; 2006 Mar 05; 316(3):1047-52. PubMed ID: 16319305
    [Abstract] [Full Text] [Related]

  • 9. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
    Fujisawa M, Yorikane R, Matsuoka Y, Koike H, Ueno K.
    J Cardiovasc Pharmacol; 2013 Jan 05; 61(1):63-9. PubMed ID: 23288106
    [Abstract] [Full Text] [Related]

  • 10. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K.
    Hypertension; 2009 Oct 05; 54(4):716-23. PubMed ID: 19667251
    [Abstract] [Full Text] [Related]

  • 11. Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
    Fujisawa M, Yorikane R, Chiba S, Koike H.
    J Cardiovasc Pharmacol; 2009 Apr 05; 53(4):325-32. PubMed ID: 19295444
    [Abstract] [Full Text] [Related]

  • 12. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
    Fujimoto S, Satoh M, Nagasu H, Horike H, Sasaki T, Kashihara N.
    Nephrol Dial Transplant; 2009 Dec 05; 24(12):3651-8. PubMed ID: 19666664
    [Abstract] [Full Text] [Related]

  • 13. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec 05; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

  • 14. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M.
    Hypertension; 2004 Feb 05; 43(2):263-9. PubMed ID: 14707152
    [Abstract] [Full Text] [Related]

  • 15. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
    Li JM, Iwai M, Cui TX, Min LJ, Tsuda M, Iwanami J, Suzuki J, Mogi M, Horiuchi M.
    Mol Pharmacol; 2005 May 05; 67(5):1666-73. PubMed ID: 15695623
    [Abstract] [Full Text] [Related]

  • 16. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
    Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, Sakaguchi M, Hougaku H, Sakoda S, Hatazawa J.
    Hypertens Res; 2008 Dec 05; 31(12):2147-54. PubMed ID: 19139604
    [Abstract] [Full Text] [Related]

  • 17. Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
    Nakamura T, Saito Y, Saito T, Kurabayashi M.
    J Pharmacol Sci; 2006 Oct 05; 102(2):239-42. PubMed ID: 17031066
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
    Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohmori K, Hosomi N, Kimura S, Kiyomoto H, Nishiyama A.
    J Hypertens; 2009 Sep 05; 27(9):1855-62. PubMed ID: 19633569
    [Abstract] [Full Text] [Related]

  • 19. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
    Nakano K, Egashira K, Ohtani K, Gang Z, Iwata E, Miyagawa M, Sunagawa K.
    Atherosclerosis; 2008 Jan 05; 196(1):172-179. PubMed ID: 17481639
    [Abstract] [Full Text] [Related]

  • 20. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial.
    Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I.
    J Cardiovasc Pharmacol; 1999 Feb 05; 33(2):186-92. PubMed ID: 10028925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.